Around the Practice® (ATP) is a virtual event featuring multidisciplinary experts in oncology discussing the latest developments in cancer care as they review patient cases. Every ATP event is unique, and we strive to deliver best-in-class awareness, so the oncology community can learn on-demand.
The Evolution of EGFR-mutated Advanced NSCLC Treatment: A Brief Review
June 27th 2025Samuel Rosner, MD, discusses how the treatment landscape for EGFR-mutated non-small cell lung cancer has evolved from first-generation targeted therapies to osimertinib as the current standard of care, while exploring emerging options like fourth-generation TKIs, antibody-drug conjugates, and bispecific therapies to overcome resistance mechanisms.
Around the Practice: Bispecifics in R/R MM: Translating Evidence into Clinical Practice
June 27th 2025Ajai Chari, MD; Ajay Nooka, MD, MPH, FACP; Muhamed Baljevic, MD; Gurbakhash Kaur, MD; and Anupama Kumar, MD, discuss how recent advances in multiple myeloma (MM) treatment, including quadruplet therapy regimens, CAR T-cell therapies in earlier lines, and emerging bispecific antibodies and trispecific agents, are transforming the treatment landscape with the potential to cure rather than just manage the disease, while addressing optimal sequencing strategies and management of adverse events across newly diagnosed and relapsed/refractory (R/R) settings.
Around the Practice: CAR T in R/R MM: Bridging Real-World Evidence and Clinical Practice
June 27th 2025Panelists discuss the evolving role of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM), highlighting its transformative impact on patient outcomes across diverse real-world settings, the importance of individualized treatment decisions based on comparative efficacy and toxicity of available therapies, innovative approaches like bridging with bispecific antibodies, strategic sequencing with other B-cell maturation antigen–targeted agents, early integration in the treatment pathway, proactive management of neurotoxicity and infections, expanding access to high-risk populations, and the critical need for collaboration between specialized centers and community providers to optimize patient care and maximize durable responses.
Advancing Treatment Strategies in Ovarian Cancer: The Evolving Role of Antibody-Drug Conjugates
May 30th 2025Leslie Randall, MD; Marion E. Cole, MD; Asim Farooq, MD, and Mallorie Haba, FNP, discuss how antibody-drug conjugates are transforming treatment strategies in recurrent ovarian cancer by offering new options for patients with platinum-resistant disease, emphasizing molecular testing, treatment sequencing, side effect management—particularly ocular toxicities—and the importance of patient-centered care.
Optimizing the Care Pathway for Advanced Epithelioid Sarcoma: Diagnosis, Treatment, and Beyond
April 16th 2025Panelists discuss how enhancing diagnostic accuracy, optimizing multidisciplinary care, and advancing treatment strategies—including targeted therapies—can improve outcomes and decision-making in patients with advanced epithelioid sarcoma (ES).
Around the Practice: Patient-Centered Decision-Making in Relapsed/Refractory Follicular Lymphoma
April 15th 2025Panelists discuss how the evolving treatment landscape in relapsed/refractory follicular lymphoma, particularly in the third-line setting and beyond, is shaping clinical decision-making through patient-centered strategies that balance efficacy, tolerability, and individualized care.
Optimizing Prostate Cancer Management: Leveraging PSMA Imaging to Enhance Treatment Strategies
March 21st 2025Jason Efstathiou, MD, DPhil, FASTRO, FACRO; Brandon Mancini, MD, MBA, FACRO; Comron Hassanzadeh, MD, MPH; and Bridget Koontz, MD, FASTRO, discuss the evolving role of PSMA PET imaging in prostate cancer, examining its impact on diagnosis, disease staging, treatment decisions, and posttreatment assessment. They also review key clinical trial data, current guideline recommendations, and real-world applications of PSMA PET imaging in practice.
DLBCL in Focus: Transforming Outcomes with CAR-T Therapy
February 25th 2025Krish Patel, MD; Saurabh Dahiya, MD, FACP; Nathan Denlinger, DO, MS; Mohamed M. Hegazi, MD, and Samuel Yamshon, MD discuss how, the DLBCL treatment landscape has evolved with CAR-T therapies transforming outcomes in R/R cases. Key considerations include risk stratification, optimal sequencing, and real-world efficacy vs. trial data. Future advances may refine patient selection, enhance manufacturing, and integrate novel therapies for improved durability and safety.
Enhancing PNH Care: Collaborative Decision-Making and Improving Patient Experience
December 18th 2024Panelists discuss how a patient-centered approach, shared decision-making, and clear communication between physicians, patients, and caregivers are essential in improving care, treatment adherence, and long-term management for individuals with paroxysmal nocturnal hemoglobinuria (PNH).
This program was made possible with support from Novartis Pharmaceuticals.
Optimizing Treatment Selection After Progression in HER2+ Metastatic Breast Cancer
December 18th 2024Panelists discuss how evolving treatment options, including T-DXd and tucatinib-based regimens, are reshaping the management of HER2+ metastatic breast cancer in later-line settings, emphasizing the importance of personalized therapy and proactive toxicity management.
Evolving Treatment Paradigms in NDMM
December 18th 2024Cristina Gasparetto, MD; Amandeep Godara, MBBS; Ken Shain, MD, PhD; and Mansi Shah, MD, examine evolving treatment paradigms in newly diagnosed multiple myeloma (NDMM), highlighting the increasing role of daratumumab-based regimens across the care spectrum—from induction through maintenance—supported by landmark trials like PERSEUS, CASSIOPEIA, and AURIGA that demonstrate improved outcomes with these approaches while considering patient-specific factors in treatment selection.
CAR T Referral Process: Insights From Kansas
December 18th 2024Al-Ola Abdallah, MD; Muhammad Umair Mushtaq, MD; Jeries Kort, MD; and Zahra Mahmoudjafari examine the evolving landscape of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma, exploring institutional challenges around patient selection, slot availability, referral processes, and decision-making frameworks while considering both clinical and practical factors that influence treatment sequencing and access.
Evolving Paradigms in Newly Diagnosed and R/R MM: Highlights from ASH 2024
December 16th 2024Panelists discuss how emerging treatment strategies, including novel induction therapies, maintenance regimens, and bispecific antibodies, are reshaping the management of newly diagnosed and relapsed/refractory multiple myeloma, with insights from ASH 2024 data and ongoing trials.
The Rapidly Evolving Treatment Landscape in PIK3CA-mutated HR+ HER2- Breast Cancer
December 10th 2024Panelists discuss how the evolving landscape of targeted therapies for PIK3CA-mutated HR+ HER2- breast cancer, including the approval of inavolisib and the growing importance of biomarker testing, is reshaping treatment strategies, patient care, and adverse event management.
Recent Updates in Bispecific Therapies for Patients With Relapsed/Refractory Multiple Myeloma
December 10th 2024Alfred Garfall, MD; Omar Nadeem, MD; Naresh Bumma, MD; and Surbhi Sidana, MD,explore the evolving therapeutic landscape of relapsed/refractory multiple myeloma, including bispecific antibodies, real-world outcomes across treatment settings, optimal sequencing strategies after CAR T progression, and long-term efficacy data from key clinical trials like MajesTEC-1.
Around the Practice: CAR-T Referral Process: Insights from MSKCC
December 9th 2024Saad Usmani, MD, MBA; Carlyn Rose Tan, MD; Sham Mailankody, MBBS, and Sridevi Rajeeve, MD, examine evolving chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, discussing recent clinical trial data for cilta-cel and ide-cel, comparing study outcomes, evaluating institutional implementation factors, and assessing patient eligibility criteria for optimal therapy selection in earlier treatment lines.
Bispecific Antibodies in Practice in Relapsed/Refractory Multiple Myeloma
October 10th 2024Panelists discuss how the introduction of bispecific antibodies is transforming the treatment landscape for relapsed/refractory multiple myeloma, addressing unmet needs and improving patient outcomes through innovative combination strategies and sequencing approaches.
Around the Practice: Optimizing Patient Referrals for Bispecifics and CAR-T Therapies
September 6th 2024Medical experts explore the optimization of patient referrals for bispecifics and CAR-T therapies through academic and community collaborations, addressing referral processes, challenges, and practical strategies with insights.
Optimizing CML Management: Shared Decision Making and Enhancing the Patient Experience
August 20th 2024A panel of experts on chronic myeloid leukemia have a comprehensive discussion on patient-centered care and the important role of shared decision-making in the optimal treatment of patients with CML.
This program was made possible with support from Novartis Pharmaceuticals.
Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management
June 25th 2024Key opinion leaders explore the integration of circulating tumor DNA and minimal residual disease assessments into clinical practice for colorectal cancer management, discussing current applications and future prospects.